Es­pe­ri­on un­veils long-await­ed da­ta on cho­les­terol pil­l's abil­i­ty to cut car­dio­vas­cu­lar risk: #ACC23

NEW OR­LEANS — Es­pe­ri­on Ther­a­peu­tics re­vealed long-await­ed da­ta on its heart pill’s ef­fi­ca­cy in cut­ting se­vere car­dio­vas­cu­lar out­comes, three years af­ter the drug was cleared for use to low­er cho­les­terol lev­els.

In the com­pa­ny’s CLEAR study of near­ly 14,000 pa­tients who are statin in­tol­er­ant, Es­pe­ri­on’s drug Nexle­tol cut the com­bined risk of heart at­tack, stroke, car­dio­vas­cu­lar death or the need for coro­nary revas­cu­lar­iza­tion by 13%, com­pared with place­bo.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN